New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 25, 2011
08:27 EDTSIGA, PIPPharmAthene, SIGA Technologies should merge, says Roth Capital
Roth Capital believes that the best course of action for PharmAthene(PIP) and SIGA (SIGA) would be to merge, although the firm adds that this isn't necessarily the most likely scenario. The firm thinks that both companies would benefit from a merger and it maintains a $6.25 target and Buy rating on PharmAthene.
News For PIP;SIGA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:16 EDTPIPPharmAthene reports Valortim IDIQ contract fulfilled
PharmAthene announced that it has fulfilled its obligations under a fixed price, indefinite delivery, indefinite quantity, or IDIQ, contract, awarded in 2013 by the Biomedical Advanced Research and Development Authority for the company's anthrax anti-toxin, Valortim. Under the IDIQ contract, PharmAthene was selected to provide a specified quantity of its Valortim anthrax anti-toxin master cell bank for secure storage by the government as part of a risk mitigation strategy for anthrax medical countermeasures.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use